PCRX logo

Pacira BioSciences (PCRX) Cash From Investing

Annual CFI

$77.54 M
+$302.73 M+134.43%

December 31, 2023


Summary


Performance

PCRX Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

Quarterly CFI

-$52.16 M
-$36.95 M-242.84%

September 30, 2024


Summary


Performance

PCRX Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

TTM CFI

-$74.53 M
-$47.82 M-179.02%

September 30, 2024


Summary


Performance

PCRX TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

PCRX Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+134.4%-1101.4%-192.8%
3 y3 years+127.9%+74.9%+57.0%
5 y5 years+276.9%+74.9%+57.0%

PCRX Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+134.4%-177.9%+74.9%-192.8%+66.9%
5 y5-yearat high+127.9%-177.9%+74.9%-192.8%+77.9%
alltimeall timeat high+127.9%-155.2%+74.9%-148.9%+77.9%

Pacira BioSciences Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2024
-
-$52.16 M(+242.8%)
-$74.53 M(+179.0%)
Jun 2024
-
-$15.21 M(-2.0%)
-$26.71 M(+540.3%)
Mar 2024
-
-$15.53 M(-285.5%)
-$4.17 M(-105.4%)
Dec 2023
$77.54 M(-134.4%)
$8.37 M(-292.9%)
$77.54 M(-3.5%)
Sep 2023
-
-$4.34 M(-159.3%)
$80.36 M(+116.1%)
Jun 2023
-
$7.33 M(-88.9%)
$37.18 M(-24.1%)
Mar 2023
-
$66.18 M(+491.5%)
$49.02 M(-121.8%)
Dec 2022
-$225.19 M(+983.1%)
$11.19 M(-123.5%)
-$225.19 M(+32.9%)
Sep 2022
-
-$47.52 M(-348.0%)
-$169.46 M(+7.9%)
Jun 2022
-
$19.16 M(-109.2%)
-$157.02 M(-9.3%)
Mar 2022
-
-$208.02 M(-410.9%)
-$173.15 M(+732.8%)
Dec 2021
-$20.79 M(-92.5%)
$66.92 M(-290.8%)
-$20.79 M(-87.8%)
Sep 2021
-
-$35.08 M(-1256.5%)
-$170.03 M(-49.7%)
Jun 2021
-
$3.03 M(-105.4%)
-$337.80 M(+10.9%)
Mar 2021
-
-$55.66 M(-32.4%)
-$304.70 M(+9.8%)
Dec 2020
-$277.61 M(+116.1%)
-$82.32 M(-59.4%)
-$277.61 M(+22.8%)
Sep 2020
-
-$202.85 M(-661.5%)
-$226.09 M(+1183.6%)
Jun 2020
-
$36.12 M(-226.5%)
-$17.61 M(-92.5%)
Mar 2020
-
-$28.57 M(-7.2%)
-$235.53 M(+83.3%)
Dec 2019
-$128.49 M(-724.5%)
-$30.80 M(-647.5%)
-$128.49 M(-41.8%)
Sep 2019
-
$5.63 M(-103.1%)
-$220.86 M(+67.3%)
Jun 2019
-
-$181.80 M(-331.6%)
-$132.02 M(-220.7%)
Mar 2019
-
$78.48 M(-163.7%)
$109.35 M(+431.4%)
Dec 2018
$20.58 M(-109.2%)
-$123.16 M(-230.4%)
$20.58 M(-86.5%)
Sep 2018
-
$94.46 M(+58.6%)
$152.44 M(+399.8%)
Jun 2018
-
$59.57 M(-678.8%)
$30.50 M(-133.8%)
Mar 2018
-
-$10.29 M(-218.3%)
-$90.22 M(-59.7%)
Dec 2017
-$223.76 M
$8.70 M(-131.7%)
-$223.76 M(-6.5%)
Sep 2017
-
-$27.48 M(-55.1%)
-$239.38 M(+6.3%)
Jun 2017
-
-$61.15 M(-57.5%)
-$225.22 M(+22.6%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$143.84 M(+1979.5%)
-$183.72 M(+197.5%)
Dec 2016
-$61.75 M(+220.7%)
-$6.92 M(-48.1%)
-$61.75 M(+29.9%)
Sep 2016
-
-$13.32 M(-32.2%)
-$47.54 M(+10.7%)
Jun 2016
-
-$19.64 M(-10.2%)
-$42.96 M(+3.9%)
Mar 2016
-
-$21.88 M(-399.8%)
-$41.33 M(+114.6%)
Dec 2015
-$19.26 M(-84.0%)
$7.30 M(-183.5%)
-$19.26 M(-20.6%)
Sep 2015
-
-$8.74 M(-51.5%)
-$24.25 M(-79.2%)
Jun 2015
-
-$18.01 M(-9105.0%)
-$116.69 M(-9.7%)
Mar 2015
-
$200.00 K(-91.3%)
-$129.25 M(+7.3%)
Dec 2014
-$120.43 M(+180.5%)
$2.31 M(-102.3%)
-$120.43 M(+12.0%)
Sep 2014
-
-$101.19 M(+231.0%)
-$107.52 M(+3854.4%)
Jun 2014
-
-$30.57 M(-439.0%)
-$2.72 M(-112.2%)
Mar 2014
-
$9.02 M(-40.7%)
$22.33 M(-152.0%)
Dec 2013
-$42.94 M(+45.4%)
$15.22 M(+321.1%)
-$42.94 M(+19.9%)
Sep 2013
-
$3.62 M(-165.5%)
-$35.80 M(-13.2%)
Jun 2013
-
-$5.52 M(-90.2%)
-$41.22 M(-50.5%)
Mar 2013
-
-$56.25 M(-351.6%)
-$83.24 M(+182.0%)
Dec 2012
-$29.52 M(-18.3%)
$22.36 M(-1336.0%)
-$29.52 M(-53.6%)
Sep 2012
-
-$1.81 M(-96.2%)
-$63.65 M(-1.2%)
Jun 2012
-
-$47.54 M(+1779.1%)
-$64.41 M(+70.3%)
Mar 2012
-
-$2.53 M(-78.5%)
-$37.82 M(+4.7%)
Dec 2011
-$36.12 M(+433.7%)
-$11.77 M(+358.8%)
-$36.12 M(+32.3%)
Sep 2011
-
-$2.56 M(-87.8%)
-$27.30 M(+2.5%)
Jun 2011
-
-$20.96 M(+2419.0%)
-$26.64 M(+270.8%)
Mar 2011
-
-$832.00 K(-71.8%)
-$7.18 M(+6.1%)
Dec 2010
-$6.77 M(+22.9%)
-$2.95 M(+55.3%)
-$6.77 M(+77.2%)
Sep 2010
-
-$1.90 M(+26.0%)
-$3.82 M(+98.7%)
Jun 2010
-
-$1.51 M(+261.2%)
-$1.92 M(+361.2%)
Mar 2010
-
-$417.00 K
-$417.00 K
Dec 2009
-$5.51 M(-5.6%)
-
-
Dec 2008
-$5.84 M
-
-

FAQ

  • What is Pacira BioSciences annual cash flow from investing activities?
  • What is the all time high annual CFI for Pacira BioSciences?
  • What is Pacira BioSciences annual CFI year-on-year change?
  • What is Pacira BioSciences quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Pacira BioSciences?
  • What is Pacira BioSciences quarterly CFI year-on-year change?
  • What is Pacira BioSciences TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Pacira BioSciences?
  • What is Pacira BioSciences TTM CFI year-on-year change?

What is Pacira BioSciences annual cash flow from investing activities?

The current annual CFI of PCRX is $77.54 M

What is the all time high annual CFI for Pacira BioSciences?

Pacira BioSciences all-time high annual cash flow from investing activities is $77.54 M

What is Pacira BioSciences annual CFI year-on-year change?

Over the past year, PCRX annual cash flow from investing activities has changed by +$302.73 M (+134.43%)

What is Pacira BioSciences quarterly cash flow from investing activities?

The current quarterly CFI of PCRX is -$52.16 M

What is the all time high quarterly CFI for Pacira BioSciences?

Pacira BioSciences all-time high quarterly cash flow from investing activities is $94.46 M

What is Pacira BioSciences quarterly CFI year-on-year change?

Over the past year, PCRX quarterly cash flow from investing activities has changed by -$47.82 M (-1101.36%)

What is Pacira BioSciences TTM cash flow from investing activities?

The current TTM CFI of PCRX is -$74.53 M

What is the all time high TTM CFI for Pacira BioSciences?

Pacira BioSciences all-time high TTM cash flow from investing activities is $152.44 M

What is Pacira BioSciences TTM CFI year-on-year change?

Over the past year, PCRX TTM cash flow from investing activities has changed by -$154.89 M (-192.75%)